Correction: HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer

PDF  |  How to cite

Oncotarget. 2021; 12:1736-1736. https://doi.org/10.18632/oncotarget.28051

Metrics: PDF 1063 views  |   ?  

Teru Hideshima1, Ralph Mazitschek2, Jun Qi1, Naoya Mimura1,5, Jen-Chieh Tseng3,6, Andrew L. Kung3,4,7, James E. Bradner1,8 and Kenneth C. Anderson1

1 Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
2 Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
3 Lurie Family Imaging Center, Dana-Farber Cancer Institute, Boston, MA, USA
4 Department of Pediatric Oncology, Dana-Farber Cancer Institute and Children’s Hospital Boston, Boston, MA, USA
5 Department of Hematology, Chiba University Hospital, Chiba, Japan
6 PerkinElmer Inc., Hopkinton, MA, USA
7 Memorial Sloan Kettering Cancer Center, New York, NY, USA
8 Novartis Institutes for BioMedical Research, Cambridge, MA, USA

Published: August 17, 2021

Copyright: © 2021 Hideshima et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: The CONFLICTS OF INTERESTS section has been updated as shown below:


K.C. Anderson is on the advisory board of Celgene, Gilead, Millennium and Bristol Myers Squibb; and is a scientific founder with financial interest in Acetylon, Oncopep and C4 Therapeutics. JB is a scientific founder with financial interest in Acetylon.

Original article: Oncotarget. 2017; 8:80109–80123. DOI: https://doi.org/10.18632/oncotarget.19019.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28051